Valeant Ad Hoc Committee Announces Completion Of Its Review Of Philidor And Related Accounting Matters
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant (VRX) Could Be on the Verge of a Significant Inflection Point - BMO Capital
April 5, 2016 10:09 AM EDTBMO Capital analyst Alex Arfaei said Valeant Pharmaceuticals (NYSE: VRX) could be on the verge of a significant inflection point after the ad hoc committee of the board of directors believes that its review of various Philidor and related accounting matters is complete and that it has not identified any additional items that would require restatements beyond those required by matters previously disclosed. The company intend to file its Form 10-K on or before April 29. The firm maintained its Market Perform rating and price target of $66.00.
Arfaei views the news as positive: "Our... More
